NBIX : Summary for Neurocrine Biosciences, Inc. - Yahoo Finance

U.S. Markets close in 3 hrs 1 mins

Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
44.51+0.35 (+0.78%)
As of 12:59PM EST. Market open.
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close44.16
Bid44.51 x 100
Ask44.55 x 100
Day's Range44.22 - 45.50
52 Week Range32.18 - 55.15
Avg. Volume1,134,825
Market Cap3.88B
PE Ratio (TTM)-27.30
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Neurocrine Biosciences, Inc. :NBIX-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017
    Capital Cube13 days ago

    Neurocrine Biosciences, Inc. :NBIX-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017

    Categories: Yahoo Finance Get free summary analysis Neurocrine Biosciences, Inc. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Neurocrine Biosciences, Inc. – Palatin Technologies, Inc., Pfizer Inc., Eli Lilly and Company and AbbVie, Inc. (PTN-US, PFE-US, LLY-US and ABBV-US) that have also reported for this period. ... Read more (Read more...)

  • Zacks Small Cap Research13 days ago

    NBIX: Acquires North American Rights to ONGENTYS® For the Treatment of Parkinson’s Disease

    ONGENTYS® is a once-daily, highly-selective catechol-O-methyltransferase (COMT) inhibitor that was approved in June 2016 by the European Medicines Agency (EMA) as an adjunct therapy along with levodopa/DOPA decarboxylase inhibitors for adults with Parkinson’s disease. Parkinson’s disease (PD) is a slowly progressing neurological disorder characterized by tremor, stiffness, slow and decreased movement, and postural instability affecting approximately 0.4% of the population over age 40 and 1% of those over age 65 (Merck Manual).

  • Thomson Reuters StreetEvents15 days ago

    Edited Transcript of NBIX earnings conference call or presentation 14-Feb-17 10:00pm GMT

    Q4 2016 Neurocrine Biosciences Inc Earnings Call